Evoke Pharma, Inc. (EVOK) News

Evoke Pharma, Inc. (EVOK): $4.54

-0.04 (-0.87%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter EVOK News Items

EVOK News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest EVOK News From Around the Web

Below are the latest news stories about EVOKE PHARMA INC that investors may wish to consider to help them evaluate EVOK as an investment opportunity.

USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe Gastroparesis

SOLANA BEACH, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the United States Patent and Trademark Office (USPTO) issued US patent No. 11,517,545 under the title “Treatment of Moderate and Severe Gastroparesis.” This patent expires in 2038 and covers the methods for treating moderate-to-

Yahoo | December 7, 2022

Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI®

SOLANA BEACH, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application No. 17/100,664 for GIMOTI. Once issued, the patent, entitled “Nasal Formulations of Metoclopramide” will expire in December 2029. This

Yahoo | November 30, 2022

Evoke Pharma Third Quarter 2022 Earnings: Beats Expectations

Evoke Pharma ( NASDAQ:EVOK ) Third Quarter 2022 Results Key Financial Results Revenue: US$832.1k (down 11% from 3Q...

Yahoo | November 12, 2022

Edited Transcript of EVOK.OQ earnings conference call or presentation 9-Nov-22 9:30pm GMT

Q3 2022 Evoke Pharma Inc Earnings Call

Yahoo | November 9, 2022

Evoke Pharma Reports Record Third Quarter 2022 Financial Results

80% increase in GIMOTI® net revenue over Q2 202256% increase of GIMOTI prescription fills in Q3 compared to Q213% increase of new prescribers of GIMOTI over Q2 SOLANA BEACH, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30, 2022 and recent corporate developments. “Evoke delivered record fi

Yahoo | November 9, 2022

Evoke Pharma to Report Third Quarter Results on November 9, 2022

SOLANA BEACH, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company is scheduled to release its third quarter on Wednesday, November 9, 2022, after the market closes. Management will host a conference call on Wednesday, November 9, 2022, at 4:30 p.m. ET to discuss the results. The dial-in numbers for the conference call are (800) 245-3047 and (203)

Yahoo | November 2, 2022

Evoke Pharma to Participate in the 2022 American College of Gastroenterology Annual Scientific Meeting

Company will exhibit Gimoti® and meet with Key Opinion Leaders Healio Industry Breakthrough Product Award Nominee SOLANA BEACH, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced that the Company will participate in the 2022 American College of Gastroenterology Annual Scientific Meeting taking place from October 21 – 26, 2022 in Charlotte, North Carolin

Yahoo | October 20, 2022

Evoke Pharma Receives Notice of Allowance from USPTO for a Patent Related to GIMOTI

SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray announced the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application No. 16/469,092 for GIMOTI. When granted, the patent will cover methods for treating moderate-to-severe gastroparesis with metoclopramid

Yahoo | September 20, 2022

GIMOTI Receives Nomination for 2022 Healio Industry Breakthrough Award

GIMOTI recognized as a major disruptor in the gastroenterology field, including several large global pharmaceutical companies Vote for GIMOTI as 2022 Healio Industry Breakthrough Product via Survey SOLANA BEACH, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that its flagship product, GIMOTI

Yahoo | September 14, 2022

Evoke Pharma to Participate in H.C. Wainwright 24th Annual Global Investment Conference

SOLANA BEACH, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced that the Company’s President and CEO, David A. Gonyer, R.Ph., and Chief Business Officer, Matt D’Onofrio, MBA, will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place from September 12-14, 2022, at the Lotte New York Palace Hotel in NYC. Details of manage

Yahoo | September 6, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5895 seconds.